University Health Network and Boehringer Ingelheim Canada Partner to Impact Patients Lives and Help a Healthcare System Under Strain

The Ontario healthcare system is under strain, still recovering from the demands of the COVID-19 pandemic. The University Health Network (UHN) and Boehringer Ingelheim (Canada) Ltd. have partnered to address a critical need of heart failure patients. The objective of the partnership is to expand patient reach of UHN’s successful Medly Program— an innovative, digital therapeutic solution that delivers the benefits of specialized clinical heart failure management at home while improving quality of life and reducing hospitalizations...READ MORE

Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office

Aurinia Pharmaceuticals Inc. announced that the United States Patent and Trademark Office has allowed a method of use patent application titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. Aurinia’s newly allowed U.S. Patent Application (No. 17/713,140) reflects the unique and proprietary dosing regimen of its currently marketed product, LUPKYNIS. Specifically, this patent further refines the method of using LUPKYNIS in combination with mycophenolate mofetil (MMF) and corticosteroids using eGFR as a method of pharmacodynamically dosing the product in patients with lupus nephritis...READ MORE

Evonik Launches Scientifically Proven Synbiotic Solutions IN VIVO BIOTICS™

Evonik has launched a new category of nutraceuticals called IN VIVO BIOTICS™. These next-generation synbiotics combine probiotics – healthy gut bacteria – with other health ingredients. IN VIVO BIOTICS™ are based on scientific understanding of human health with deep knowledge of the market for food ingredients and dietary supplements. Customers working on innovative nutraceuticals and health solutions benefit from Evonik’s superior expertise in biotechnology and formulation, as well as reliable delivery, excellent quality standards and scalable production...READ MORE

Gandeeva Therapeutics Announces Appointment of Dr. Brenda G. Cooperstone to its Board of Directors

Gandeeva Therapeutics, Inc., a biotechnology company focused on designing and developing precision therapeutics guided by cryogenic electron microscopy (cryo-EM) and machine learning, announced the appointment of Brenda G. Cooperstone, MD, as an independent member of its Board of Directors. Dr. Cooperstone is a pharmaceutical executive with more than 20 years of experience in drug development. She most recently served as the Chief Development Officer, Rare Diseases and the Pennsylvania Site Head for Pfizer Inc...READ MORE

PharmAla Biotech Granted an Export Permit for 300 Grams of LaNeo™ MDMA

PharmAla Biotech Holdings Inc., a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules (including MDMA) and its manufacturing partners have received an export permit for 300 grams of its LaNeo™ MDMA. PharmAla believes this is the largest single Health Canada export permit ever granted by weight to date...READ MORE

Dr. Matt Cahill Appointed Chief Operating Officer of Qu Biologics

Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce the appointment of Matt Cahill MBA JD PhD, as Chief Operating Officer...READ MORE

AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent

AbCellera announced that the United States Patent and Trademark Office’s Patent Trial and Appeal Board has ruled in favor of AbCellera in an Inter Partes Review filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera’s U.S. Patent No. 10,087,408 (the ‘408 Patent). AbCellera’s ‘408 Patent is directed to microfluidic devices and using such devices to culture cells, monitor a response, and recover selected cells...READ MORE

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months From Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Jazz Pharmaceuticals plc and Zymeworks Inc. announced tolerability and efficacy results, including the first overall survival (OS) data, from a Phase 2 trial examining zanidatamab, an investigational HER2-targeted bispecific antibody, in combination with chemotherapy, in first-line patients with HER2-expressing metastatic gastroesophageal adenocarcinoma...READ MORE

PR Associates Grows Executive Team with Addition of Michael MacMillan as Vice President (JAN 11)

PR Associates National Communications Ltd. (PR Associates), a premier Canadian public relations firm, is pleased to announce the appointment of Michael MacMillan as Vice-President of Client Services. In this role, Michael will work closely with the clients of PR Associates, prioritizing each client’s unique needs, and positioning them to fully benefit from the deep experience and unique expertise of PR Associates...READ MORE

Government of Canada Announces New Clinical Trials Consortium, Training platforms, and Research Projects to Improve the Health of Canadians

As part of Canada’s Biomanufacturing and Life Sciences Strategy (BLSS), the Canadian Institutes of Health Research (CIHR) Clinical Trials Fund (CTF) will be foundational in ensuring that Canadians are well served by a national clinical trials network that fosters all aspects of therapeutics development, from discovery through to delivery. It will be crucial to preparedness for future pandemics or other health emergencies and to grow a strong life sciences sector...READ MORE

Innovate BC and NRC IRAP Invest in British Columbia Businesses Through BC Fast Pilot Program

Innovate BC and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) are providing a combined total of $2 million in research and development funding to help 14 companies pilot their technologies and create new jobs across BC. The program helps small and medium sized businesses design, build, and operate a pilot plant or small demonstration of their technology while helping to solve real world problems...READ MORE

Senior Engineer, Process Development

Abdera is seeking a Senior Engineer, Antibody and Antibody-Conjugate Process Development, to lead process development of antibody and drug conjugation that advances the company’s clinical programs. This role will be essential to ensure phase-appropriate process development and optimization of antibody and drug conjugate manufacturing of our novel oncology therapy candidates. The Senior Engineer is responsible for process development and manufacturing of antibodies and antibody-chelate-conjugates and drive the related CMC elements throughout the product life cycle of antibody-based radiopharmaceuticals.

LEARN MORE

Senior Manager/Director, Strategic & Technical Marketing

Evonik’s Health Care Drug Delivery & Products business provides polymeric and lipid-based parenteral drug delivery solutions to life science and pharmaceutical industries by offering contract development and clinical and commercial phase GMP-compliant manufacturing services, as well as advanced processing equipment technologies under the brand name LIPEX®. This position will support the services-based business and promote its growth to ensure the Parenteral Drug Delivery Solutions Segment and the Vancouver site are recognized as the leading CDMO by the pharmaceutical industry for polymeric, liposomal and lipid nanoparticle drug development and products.

LEARN MORE

Contract Software Developer, Java/Python

Semaphore is seeking an experienced Software Developers who has a strong working knowledge of Python or Java. Experience working in the domain of genomics, clinical laboratories or health science is an asset but not required. This opportunity is to support projects that will require additional technical support outside the current team over a fixed term. Projects often include working within the customer team, so an ability to communicate effectively directly with customers is a critical component of the role. Success in the role is tied to understanding project requirements and translating them into high-quality code, with an ability to balance the timely delivery of milestones.

LEARN MORE

Renaissance BioScience is an environmental impact company whose bioengineering platform technologies develop innovative, market-ready, functional microorganisms that provide solutions to a broad range of health and environmental problems. Based in Vancouver, Canada, Renaissance is currently developing technologies for the oral delivery of RNA, targeting human and animal health, biopesticides and aquaculture solutions.

RNAi and mRNA are valuable and revolutionary technology that has been widely applied in medicine and agriculture facilitating sustainable practices and technologies that combine effectiveness with a minimal environmental footprint.

Visit Website

Molecular You is driving the personalized medicine revolution with advanced health analytics using multi-omic biomarkers. Their phenomics, genomics, metabolomics, proteomics and exposomics combine to provide high accuracy and predictability in support of the drug discovery and development processes.

More specifically, Molecular You health intelligence provides valuable insights related to biological pathways, effectiveness of drug performance, efficacy and safety over time and the identification of co-morbidity risk. Because their intelligence is RWD, it can also be used as supplemental patient information in the development process. In the early drug discovery process, Molecular You can provide valuable insights related to biological pathways in humans for target selection and validation, stratify patient populations from responders and non-responders for more efficient drug development.

Visit Website